In Vivo Smooth Muscle Cell-Specific CRISPRi Perturb-seq - Baseline Condition (4 weeks no diet, no ApoE) v2

Read full text Summarise with VIRAT
Authors: João P. Monteiro, Daniel Yuhang Li
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

This protocol describes an in vivo smooth muscle cell (SMC)-specificPerturb-seq workflow enabling targeted gene repression and single-cell transcriptional profiling during atherosclerosis. Using Myh11CreERT2; ROSAtdT/+; dCas9KRAB mice, dCas9-KRAB expression is induced in adult SMCs via tamoxifen administration. One week after tamoxifen induction, mice receive a single systemic AAV injection via retro-orbital delivery under isoflurane anesthesia to introduce sgRNAs targeting genes of interest or non-targeting controls. At defined endpoints, aortic roots are harvested and enzymatically dissociated to generate single-cell suspensions. Dual-positive tdTomato⁺/GFP-reporter⁺ cells are isolated by FACS and processed using the 10x Genomics Chromium platform for single-cell RNA sequencing and CRISPR guide capture. This integrated workflow enables high-resolution, lineage-traced functional genomics in vivo, allowing assessment of SMC state transitions and gene regulatory perturbations.

Fields of Study & Subjects

CRISPR and Genetic Engineering Atherosclerosis and Cardiovascular Diseases Single-cell and spatial transcriptomics

Publication details

Publication date
26 February 2026
Language
EN
Document type
Preprint